Lack of Mass. IPOs mirrors national trends in ‘slowest Q2 since Great Recession’


At the midpoint of the year, only five biotech companies based in Greater Boston went public since the beginning of 2022, and zero local tech companies hit the public markets through a traditional initial public offering.

Previous UBMD Ophthalmology plans $9.6M expansion to expand access to care
Next How this Raleigh startup is reinventing collagen for biopharma, food and cosmetics